Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.62 |
| ▸ | TDP2 | O95551 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201301 | 0.84 | MAPT (0.54) | TDP2MAPTTDP1NPC1RAB9A | |
| SCHEMBL30227178 | 0.79 | ALDH1A1 (0.45) | PGRMAPTTDP1SMN1; SMN2NPC1 | |
| SCHEMBL3526223 | 0.77 | PGR (1.00) | PGRTDP2 | |
| SCHEMBL429310 | 0.75 | MAPT (0.57) | PGRTDP2MAPTTDP1NPC1 | |
| SCHEMBL6540904 | 0.75 | PGR (0.61) | PGRTDP2MAPTIDO1TDP1 | |
| SCHEMBL6541741 | 0.75 | PGR (0.61) | PGRTDP2MAPTIDO1TDP1 | |
| SCHEMBL6539077 | 0.75 | PGR (0.61) | PGRTDP2MAPTIDO1TDP1 | |
| SCHEMBL14311716 | 0.74 | PGR (0.63) | PGRTDP2MAPTIDO1LMNA | |
| Hydrochloric Acid SCHEMBL4967505 | 0.74 | MAPT (0.56) | PGRTDP2MAPTTDP1NPC1 | |
| SCHEMBL3877014 | 0.74 | PGR (0.76) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175397-B1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | WYETH CORP (US) | 2004-08-18 | — | — | EP | claimed |
| US-6503939-B2 | That are antagonists of the progesterone receptor, in a female contraceptive kit | WYETH | 2003-01-07 | — | — | US | claimed |
| JP-2002543157-A | — | — | 2002-12-17 | — | — | JP | claimed |
| JP-2002543181-A | — | — | 2002-12-17 | — | — | JP | claimed |
| US-6417214-B1 | COMPOUNDS AS CONTRACEPTIVES | WYETH | 2002-07-09 | — | — | US | claimed |
| EP-1175397-A1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-01-30 | — | — | EP | claimed |
| EP-1173211-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | claimed |
| US-6329416-B1 | ADMINISTERING TO FEMALE OF CHILD BEARING AGE FOR 28 CONSECUTIVE DAYS: FIRST PHASE DOSAGE OF PROGESTATIONAL AGENT; SECOND PHASE OF ANTIPROGESIN COMPOUND, AND THIRD PHASE OF PLACEBO FOR CONTRACEPTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-11 | — | — | US | claimed |
| WO-2000066554-A1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| WO-2000066166-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| US-6835744-B2 | For therapy of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors | WYETH | 2004-12-28 | — | — | US | disclosed |
| EP-1175397-B1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | WYETH CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030008909-A1 | 3,3-substituted indoline derivatives | WYETH (US) | 2003-01-09 | — | — | US | disclosed |
| US-6503939-B2 | That are antagonists of the progesterone receptor, in a female contraceptive kit | WYETH | 2003-01-07 | — | — | US | disclosed |
| US-6417214-B1 | COMPOUNDS AS CONTRACEPTIVES | WYETH | 2002-07-09 | — | — | US | disclosed |
| CN-1349500-A | 3,3-substituted indoline derivatives | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| US-20020035099-A1 | Combination regimens using 3,3-substituted indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
| EP-1173211-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6329416-B1 | ADMINISTERING TO FEMALE OF CHILD BEARING AGE FOR 28 CONSECUTIVE DAYS: FIRST PHASE DOSAGE OF PROGESTATIONAL AGENT; SECOND PHASE OF ANTIPROGESIN COMPOUND, AND THIRD PHASE OF PLACEBO FOR CONTRACEPTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-11 | — | — | US | disclosed |
| WO-2000066166-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008909-A1 | 3,3-substituted indoline derivatives | NR3C2, PGR, HTR3C | PGR 2/4885TDP2 3467/4885MAPT 3400/4885 |
| US-20020035099-A1 | Combination regimens using 3,3-substituted indoline derivatives | MC2R, PRLHR, MC5R | PGR 6/4885TDP2 4675/4885MAPT 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.